Journal article
Antiangiogenic therapies in non-small-cell lung cancer
Abstract
Angiogenesis is frequent in non-small-cell lung cancer (nsclc) and is associated with more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic therapy to standard therapies for patients with nsclc. Bevacizumab, a monoclonal antibody directed against serum vascular endothelial growth factor, in combination with carboplatin-paclitaxel chemotherapy, has been shown to improve survival for patients with nsclc. …
Authors
Alshangiti A; Chandhoke G; Ellis PM
Journal
Current Oncology, Vol. 25, No. 0, pp. 45–58
Publisher
MDPI
Publication Date
June 2018
DOI
10.3747/co.25.3747
ISSN
1198-0052